Welcome to NuPotential

NuPotential is pioneering the discovery and development of novel drugs that modulate epigenetic targets and their processes for the treatment of cancer. NuPotential’s proprietary PIER drug discovery platform stems from foundational discoveries linking small molecule epigenetic pathway modulation to cellular reprogramming. Founded in 2007 on the discoveries of Dr. Kenneth Eilersten, Associate Prof., Louisiana State University, when he discovered that modifying a single biochemical pathway could alter key epigenetic modifications in a number of diseases with significant unmet need such as cancer, autoimmune disorders and neurodegenerative diseases.

NuPotential’s lead compounds focus on inhibiting G9a and DNMT1 and their impact on Triple-Negative Breast Cancer (TNBC) and Acute Myeloid Leukemia (AML), respectively.

  • 2

    Science Overview

    Epigenetics is the study of changes in gene expression, cellular phenotype or function caused ... READ MORE

  • 4


    NuPotential is developing compounds that inhibit G9a, a key epigenetic target... READ MORE

  • 1


    NuPotential is developing compounds that inhibit DNA methyltransferase 1 (DNMT1)... READ MORE

  • 3


    NuP is working on developing compounds that inhibit two key epigenetic targets...READ MORE

Our Management

View All

Kenneth Eilertsen

PhD, President/Founder

Dr. Eilertsen is a world recognized leader in the epigenetics and somatic cell nuclear transfer and founded Nu...

Joan Neuscheler


Ms. Neuscheler joined NuPotential in 2010 and oversees the business operations for the Company.She has more th...

Latest News/Events

View All

NuPotential to Prese..

San Francisco, CA - Dr. Kenneth Eilertsen will present a company overview at Biotech Showcase on January 13th ... read more

Dr Kenneth Eilertsen..

Boston, July 21, 2015.  Dr. Kenneth Eilertsen was invited to present a talk entitled "Preclinical Development... read more

VistaGen Therapeutic..

SOUTH SAN FRANCISCO, Calif., & BATON ROUGE, La.--(BU... read more